Lund, Sweden, 2013-05-13 08:57 CEST (GLOBE NEWSWIRE) --
A new study published in Eur J Nucl Med Mol imaging shows that EXINI heart (ExH) software with its advanced adjustment of algorithms is a superior tool for improved quantification of small hearts for gated myocardial perfusion imaging. The size of the heart is important and in patients with small hearts, for example women, new, adjusted imaging methods are necessary for a more accurate processing. The aim of the study was to develop a new method for delineation of the left ventricle (LV). The conclusion of the study is that the adjusted EXINI heart (ExH) software provides a more uniform ejection fraction (EF) between genders and between small and normal-sized hearts.
Dr Kenichi Nakajima, Kanazawa University,
“Earlier software has been problematic for accurate quantification of small hearts for gated myocardial perfusion imaging. We think we have solved this problem now with a prototype of EXINI heart using an active shape-based model for the software algorithm. I am looking forward to further evaluation and use of the product in my clinical practice.”
Professor Lars Edenbrandt, Scientific Director at EXINI Diagnostics AB,
“It is really exciting to strengthen our excellent collaboration with FUJI Film and Japanese Universities further and to continue the development of our heart product for the international market.”
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
